Wes Reisz discusses the shift toward AI-first software delivery, emphasizing that agentic workflows are not one-size-fits-all ...
Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results